Tonoarteriography (TAG) on Watch


A multimodality wearable, flexible and intelligent sensing devices including TAG watches, for monitoring the multi-predictors of CVDs, especially for the continuous and unobtrusive measurements of arterial blood pressure.

  • Tonoarteriography (TAG) on Watch 0
  • Tonoarteriography (TAG) on Watch 1
Commercialisation opportunities
Patent licensing, startup company
Problem addressed

Wearable cuffless blood pressure measurement.

  • A ML model for stable and dynamic TAG estimation.
  • A compact multi-modal physiological signal sensing module for better TAG estimation performance.
  • A novel BP calibration algorithm to enable arm gesture free BP estimation.
Key impact
  • Realize wearable cuffless BP monitoring without interference to daily life adn suitable for nighttime BP monitoring.
  • Calibrate BP measurement to heart-level BP, realize unobtrusive BP monitoring.
  • Joint paper with Oxford University received 3rd Prize in the 2022 IEEE Engineering in Medicine and Biology Prize Paper Award.
  • Joint paper with Oxford University ranked within the top 5 among the 50 monthly popular papers published by R-BME over the last 30 months.
  • Joint paper with Oxford University highlighted as the front cover of R-BME Volume 14.
  • integrated into wearable devices for multimodal physiological signal monitoring, such as watches, earphones.
  • acquire multimodal physiological signals for database establishment.


  • A Multi-Modal Sensor Module And A Multi-Modal Physiological Signal Monitoring System 17/972,952(US), 202221308988.4 (CN)
  • A Method, A Device, An Electronic Apparatus And A Storage Medium For Processing Multi-Modal Physiological Signals 17/981,392(US),202210556950.7 (CN)

Cerebro-Cardiovascular Disease (CVD) has been the world’s leading cause of morbidity and mortality as well as the health industry’s most costly disease for treatment. Yet, despite recent advances in its treatment, more effective and accessible ways to tackle CVDs remain to be discovered. Hong Kong Centre for Cerebro-cardiovascular Health Engineering (COCHE) is taking on the challenge to develop new ways to control and prevent CVDs with innovative technologies allowing early prediction and intervention, so people can stay a step ahead of the disease. These technologies can also reduce human cost, as well as alleviate both the economic and social burdens, on the healthcare system.

In collaboration with the University of Oxford and the Karolinska Institutet, Hong Kong Centre for Cerebro-cardiovascular Health Engineering (COCHE) was established under City University of Hong Kong in December 2020. COCHE, supported financially by Innovation and Technology Commission (ITC), was admitted to Inno-Health cluster of InnoHK Programme which is a major R&D initiative of the Hong Kong Special Administrative Region Government.